Related Experiment Video

Updated: Aug 19, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Recent advances in defining the role of misoprostol in rheumatology

P A Nicholson1

  • 1Searle Research and Development, Skokie, IL 60077.

The Journal of Rheumatology. Supplement
|February 1, 1990
PubMed

Insights

Misoprostol, a prostaglandin E1 analog, demonstrates potent anti-inflammatory and immunomodulatory effects. It enhances the efficacy of other drugs and may protect cartilage from NSAID-induced damage.

Area of Science:

  • Pharmacology
  • Immunology
  • Inflammation Research

Background:

  • Prostaglandin E1 analog misoprostol shows potential anti-inflammatory and immunomodulatory properties.
  • Existing research indicates misoprostol may enhance the effects of immunosuppressants and protect against drug-induced tissue damage.

Purpose of the Study:

  • To investigate the anti-inflammatory and immunomodulatory effects of misoprostol.
  • To evaluate misoprostol's impact on drug efficacy and its protective potential against cartilage damage.

Main Methods:

  • Utilized the carrageenan acute inflammation rat model to assess misoprostol's effect with diclofenac.
  • Reviewed in vitro and animal studies on misoprostol's interaction with cyclosporine and steroids.
  • Analyzed data from renal transplant recipients treated with misoprostol, cyclosporine, and steroids.
  • Examined misoprostol's role in mitigating cytokine synthesis and preventing NSAID-induced cartilage damage.

Main Results:

  • Misoprostol significantly reduced the required dose of diclofenac in an acute inflammation model.
  • Misoprostol amplified the immunomodulatory effects of cyclosporine and steroids in various studies.
  • Renal transplant recipients showed improved function and reduced graft rejection with misoprostol addition.
  • Misoprostol demonstrated potential to decrease cytokine synthesis, offering protection against NSAID-induced cartilage damage.

Conclusions:

  • Misoprostol exhibits significant anti-inflammatory and immunomodulatory activities.
  • The combination of misoprostol with other agents like diclofenac, cyclosporine, and steroids enhances therapeutic outcomes.
  • Misoprostol warrants further investigation for its broad therapeutic applications in inflammation, immunosuppression, and tissue protection.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...